Pharmacogenetics: From Bench to Byte— An Update of Guidelines

  title={Pharmacogenetics: From Bench to Byte— An Update of Guidelines},
  author={J. J. Swen and Marga Nijenhuis and Antonius de Boer and L. Grandia and A. H. Maitland‐van der Zee and H Mulder and GA Rongen and R H N Schaik and Tom Schalekamp and D. J. Touw and Jan van der Weide and Bob Wilffert and V H Deneer and H. J. Guchelaar},
  journal={Clinical Pharmacology \& Therapeutics},
Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics‐based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine‐S… 
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of
Cytochrome P450 genotype‐guided drug therapies: An update on current states
Prospect for routine clinical application of CYP genotyping before prescribing drugs is still currently unclear due to challenges and barriers associated with availability of well‐defined and validated pharmacogenetic studies, the interpretation, result reporting and potential error of genotype testing, involvement of non‐genetic factors, and other patient's demographic and disease conditions.
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
An overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice is provided and a summary of the relevant SNPs and the recommendations on how to apply their results has been compiled.
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP1C19 Genotypes and Dosing of Tricyclic Antidepressants.
Pharmacogenomics guidelines: Current status and future development
Differences by head‐to‐head comparison of the existing pharmacogenomics guidelines are discussed and new strategies for their future development are proposed.
Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
This chapter describes a process of developing evidence based drug dosing and pharmacotherapeutic guidelines per genotype by the Dutch Pharmacogenetics Working Group, aimed to provide recommendations in case drugs are prescribed to a patient whose genotype is known.
Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel
A minimum gene and allele set for pharmacogenetic testing in psychiatry that includes 16 variant alleles within five genes (CYP2C9, CYP2C19, CyP2D6, HLA-A, H LA-B) is proposed to assist clinicians in judging the gene and phenotype content of pharmacogenetics tests and to facilitate pharmacogenetically testing as a standard protocol and companion tool for psychotropic medication selection and dosing.
Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain
Suggestions and areas of focus are provided to develop a guide for clinical practice in pharmacogenomics testing, and the relative importance of 29 gene/drug pairs in the Spanish study are compared with those in the American Society for Clinical Pharmacology and Therapeutics study.
Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.
The genomic complexities of CYP2D6, current sequencing methods and the evolution of CYD6 from allele discovery to clinical pharmacogenetic testing are highlighted.


Pharmacogenetics: From Bench to Byte
The use of pharmacogenetic recommendations in routine clinical practice remains difficult, because they are currently outside the ambit of the clinical environment and are not accessible during the decision‐making process by physicians and pharmacists, namely the prescription and dispensing of drugs.
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial will assess, in a single-blinded and randomized controlled trial with a follow-up period of 3 months, the safety and clinical utility of genotype-guided dosing in daily practice for the three main coumarin derivatives used in Europe.
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP1C19 to provide a useful complementation to clinical monitoring and therapeutic drug monitoring.
Clinically Available Pharmacogenomics Tests
The development of robust and clinically valuable pharmacogenomic tests has been anticipated to be one of the first tangible results of the Human Genome Project. Despite both obvious and
Role of warfarin pharmacogenetic testing in clinical practice.
The pharmacogenetics of warfarin metabolism and the clinical role of genetic testing forwarfarin therapy are reviewed and it is suggested that the pharmacogenomics-guided dosing algorithm can accurately predict warFarin dosage and might reduce adverse events.
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
Genetic variants of the VKORC1 gene locus modulate the mean daily dose of drug prescribed to acquire the target anticoagulation intensity and accounted for about a third of the interindividual variability in the present setting.
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries.
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
The gene vitamin K epoxide reductase complex subunit 1 (VKORC1), which encodes a small transmembrane protein of the endoplasmic reticulum, is identified, by using linkage information from three species, to be involved in two heritable human diseases.
Identification of the gene for vitamin K epoxide reductase
Vitamin K epoxide reductase (VKOR) is the target of warfarin, the most widely prescribed anticoagulant for thromboembolic disorders. Although estimated to prevent twenty strokes per induced bleeding
Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
In 130 volunteers, CYP2C9 activity was measured in vivo using tolbutamide as a probe drug, and the pharmacokinetics of the drug was analyzed twice—before and after four doses of 450 mg rifampin.